Sarcoma  >>  carotuximab IV (ENV-105)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
carotuximab IV (ENV-105) / Kairos Pharma
TAPPAS, NCT02979899 / 2016-000485-34: Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma

Checkmark From TAPPAS trial in combination with TRC105 for angiosarcoma
May 2020 - May 2020: From TAPPAS trial in combination with TRC105 for angiosarcoma
Checkmark Interim analysis of TAPPAS trial for angiosarcoma [trial terminated]
Apr 2019 - Apr 2019: Interim analysis of TAPPAS trial for angiosarcoma [trial terminated]
Checkmark Results in combination with Votrient for angiosarcoma [TAPPAS]
More
Completed
3
128
Europe, US
TRC105, anti-endoglin antibody, carotuximab, Votrient, pazopanib
Tracon Pharmaceuticals Inc.
Advanced Angiosarcoma
04/19
08/19

Download Options